Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herbal fen-phen products are unapproved new drugs, FDA tells consumers.

This article was originally published in The Tan Sheet

Executive Summary

"HERBAL FEN-PHEN" PRODUCTS ARE UNAPPROVED NEW DRUGS, FDA declares in a "Talk Paper" issued Nov. 6. Because the herbal products' names "reflect that they are intended for the same use as the anti-obesity drugs, fenfluramine and phentermine," the products are unapproved new drugs that "have not been shown to be safe or effective and may contain ingredients that have been associated with injuries," the agency states. Wyeth-Ayerst recently withdrew Pondimin (fenfluramine) and Redux (dexfenfluramine) from the market due to adverse events associated with coronary artery valves and primary pulmonary hypertension.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel